Chris Schott

facebook_page
twitter_page

Last quote by Chris Schott

On 2017, we see an upward bias to numbers on an operational basis based on the ongoing product cycle. With President Trump's drug pricing commentary over the past few weeks, we have seen renewed investor focus on this topic. Nonetheless, we do not see any wholesale shift in the current healthcare market structure in the foreseeable future.
Jan 24 2017
Chris Schott has been quoted in 2 different articles. Most recently, Chris Schott has been quoted saying, “While we have admittedly supported the stock through recent controversies on a valuation basis (and we continue to see an attractive SOTP valuation case), we are moving to the sidelines as we see a number of uncertainties around core business trends that are unlikely to be resolved in the near-term.” in an article called JPMorgan downgrades Valeant on earnings uncertainty. This is only one of 2 quotes from Chris Schott. To see more examples Chris Schott’s views and opinions, check out the section below. You can filter Chris Schott's quotes by date and by topic to see, for example, what Chris Schott said about valuation recently and in the past.
Automatically powered byStoryzy

Quotes by Chris Schott

<
facebook_page
twitter_page
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided